Nordisk
Novo Nordisk’s Saxenda Demonstrates Significant Weight Loss in Children Aged 6-12 in Phase III Trial
Saxenda, Novo Nordisk, pediatric obesity, weight loss, Phase III trial, EASD24
Novo Nordisk Reports Significant Weight Loss with New Dual-Acting Oral Drug in Early Clinical Trial
Novo Nordisk, weight loss, dual-acting oral drug, early clinical trial, obesity treatment, GLP-1 receptor agonist
BioAge Labs Files for $100 Million IPO to Advance Obesity Treatment Candidate Azelaprag
BioAge Labs, IPO, Obesity Treatment, Azelaprag, Eli Lilly, Novo Nordisk, Clinical Trials
Novo Nordisk Unveils Enhanced Cardiovascular Benefits of Semaglutide in Post-Hoc Analysis
Semaglutide, Cardiovascular Outcomes, Obesity, Type 2 Diabetes, Novo Nordisk, Post-Hoc Analysis
Novo Nordisk Invests $221 Million in New Danish Plant to Enhance Supply Chain
Novo Nordisk, supply chain, Danish plant, investment, pharmaceuticals
Novo Nordisk’s Wegovy Approved in China: Implications and Future Challenges
Novo Nordisk, Wegovy, semaglutide, obesity treatment, China approval, generic competition, patent expiration, pharmaceutical market
Novo Nordisk Pursues FDA Filing for Once-Weekly Insulin and Semaglutide Combo After Icodec Rejection
Novo Nordisk, insulin icodec, semaglutide, FDA filing, type 2 diabetes, once-weekly insulin, IcoSema, COMBINE-1 study, regulatory approval
Novo Nordisk’s Once-Weekly Insulin Icodec Faces FDA Rejection and Manufacturing Concerns
Novo Nordisk, icodec, FDA rejection, once-weekly insulin, manufacturing issues, type 1 diabetes, type 2 diabetes, semaglutide, IcoSema
Novo Nordisk’s Wegovy Sales Shortfall: A Rare Setback for the Danish Drugmaker
Novo Nordisk, Wegovy, weight-loss drug, sales shortfall, stock performance, pharmaceutical industry
Novo Nordisk Expands Legal Campaign Against Compounders of GLP-1 Drugs
Novo Nordisk, GLP-1 drugs, compounded drugs, legal campaign, patient safety, semaglutide